CEO Leads Major $9M Buy at Boston Scientific Corp.
Boston Scientific Corporation (BSX:US) is a global leader in medical devices, developing and manufacturing innovative solutions across interventional cardiology, endoscopy, neuromodulation, urology, and other specialties. The company operates through two primary segments, MedSurg and Cardiovascular, and serves healthcare providers worldwide. As of early August 2026, Boston Scientific has a market capitalization of approximately $70-72 billion.
CEO Leads Significant Open-Market Purchases
Insider activity at Boston Scientific was strongly positive in late July and early August 2026, led by a substantial open-market purchase from the CEO:
Michael F. Mahoney (Chairman, President and CEO) on August 3, 2026 purchased 186,240 shares at $48.332 per share for $9.001 million, increasing his holdings to approximately 1.59 million shares. On the same day he also acquired 22,119 shares (likely through equity awards).
David C. Habiger (Director) bought a total of 1,182 shares across August 3-4 for approximately $56,886.
Edward J. Ludwig (Lead Independent Director) purchased 5,000 shares on July 31, 2026 at $45.48 per share for $227,399.
Michael Mahoney’s large personal investment carries significant weight. As Chairman, President and CEO, his decision to deploy substantial capital into company shares shortly after recent market pressure demonstrates strong personal conviction in Boston Scientific’s long-term strategy and current valuation.
Q2 Results and Guidance Update
Boston Scientific reported solid Q2 2026 results on July 29, with revenue of $5.44 billion (up 7.5% year-over-year) and adjusted EPS of $0.86, both beating expectations. However, the company lowered its full-year 2026 guidance, citing challenges in the electrophysiology and Watchman businesses. The guidance cut contributed to share price weakness in the following days.
The substantial insider buying, particularly the CEO’s $9 million purchase, occurred in the period following this guidance revision and the associated share price pullback.
Overall, the significant open-market purchases by the CEO, a director, and the Lead Independent Director represent a strong positive signal. Leadership appears to view the recent share price levels as an attractive entry point despite near-term guidance adjustments.
